+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 100 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate whether adding a traditional Chinese medicine called Lingze tablets to the standard drug tamsulosin can better improve sleep quality and reduce nighttime urination problems in men who have undergone transurethral holmium laser enucleation of the prostate, a minimally invasive surgery for enlarged prostate. Many men continue to experience bothersome urinary symptoms and poor sleep after surgery, which can significantly affect their quality of life. This trial compares standard treatment to a combination approach to see if the addition of Lingze tablets offers added benefits. Participants will be randomly assigned to one of two groups. One group will take tamsulosin sustained-release capsules 0.2 mg orally once daily at bedtime for 8 weeks. The other group will take the same tamsulosin dose plus Lingze tablets 4 tablets, three times daily for 8 weeks. Lingze tablets are herbal-based and thought to support kidney function and clear bodily dampness and heat according to traditional Chinese medicine. Both groups will receive standard postoperative care guidance on diet, fluid intake, and activity. During the study, participants will visit the clinic at the start, 4 weeks, and 8 weeks for assessments. They will complete questionnaires on urinary symptoms, sleep quality, anxiety, and quality of life. Non-invasive urine flow tests and bladder ultrasounds will measure urinary function. Medication adherence and any side effects will be monitored. The primary outcome is the change in nighttime urination frequency over 8 weeks, with secondary outcomes including sleep quality and symptom severity. Safety and privacy are carefully maintained throughout the study.

Age: 50Years +MALEPhase 4
1 location
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQH3906 capsules, a once-daily oral medication, in adults aged 18 to 75 with moderate to severe plaque psoriasis. This multicenter, randomized, double-blind, placebo- and active-controlled Phase III trial compares TQH3906 with deucravacitinib and placebo. TQH3906 selectively inhibits TYK2, targeting inflammatory pathways involved in psoriasis, aiming to support its approval for treating this condition. Participants are randomly assigned in a 221 ratio to receive TQH3906 capsules 24 mg, deucravacitinib tablets 6 mg, or placebos matching each drug during a 16-week double-blind treatment phase. After this, all participants enter a 36-week open-label extension where they receive TQH3906 capsules alone. Following treatment, there is a 4-week safety follow-up period to monitor any lasting effects. Throughout the study, participants undergo regular assessments including the static Physicians Global Assessment sPGA and Psoriasis Area and Severity Index PASI to measure skin improvement up to 16 and 52 weeks. Additional evaluations focus on scalp, nail, and palmoplantar psoriasis, quality of life via the Dermatology Life Quality Index DLQI, and drug levels in the body. Safety is closely monitored during and after the treatment periods to gather comprehensive data over a year.

Age: 18Years - 75YearsAll GendersPhase 3
45 locations
O

Actively Recruiting

Researchers are evaluating STI-7349, a new drug administered intravenously, in adults with advanced solid tumors who have failed or cannot tolerate standard treatments. This first-in-human Phase 1 study involves dose escalation and expansion phases to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of STI-7349 alone and in combination with Pembrolizumab or other approved PD-1PD-L1 inhibitors like Tislelizumab. The study aims to determine the recommended doses for further research and to evaluate treatment-related side effects over up to two years. The study is divided into two main periods. Period I includes dose escalation and expansion of STI-7349 alone, starting with low doses and gradually increasing following specific schedules over 21 to 28-day cycles with dosing on Day 1 and Day 15. Period II involves dose escalation and expansion of STI-7349 combined with Pembrolizumab or other approved PD-1PD-L1 inhibitors, using doses based on the results from Period I. Participants receive these combinations following similar dosing schedules and may also receive standard treatment alongside the study drugs depending on the stage of their condition. Participants will undergo regular dosing cycles lasting up to two years or until disease progression, unacceptable side effects, or withdrawal. Throughout the study, researchers will monitor safety through treatment-related adverse events, pharmacokinetic profiles including drug concentration levels, and measure tumor response using imaging techniques. Additional assessments include survival rates, disease control, and immune response markers. Participants will complete scheduled visits for drug administration and evaluations, with ongoing safety follow-up to understand the effects of the treatments.

Age: 18Years - 80YearsAll GendersPhase 1Phase 2
1 location
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
S

Actively Recruiting

Esophageal squamous cell carcinoma ESCC is a common and deadly cancer in China, with many patients diagnosed at advanced stages. This study evaluates a combined treatment approach using induction immunochemotherapy followed by concurrent chemoradiotherapy, aiming to improve outcomes for patients with locally advanced, unresectable ESCC. Researchers also focus on using circulating tumor DNA ctDNA to monitor treatment response and predict tumor progression, as ctDNA changes can appear before imaging detects recurrence. Participants receive induction immunochemotherapy consisting of toripalimab combined with paclitaxel and cisplatin every three weeks for two cycles. This is followed by radical concurrent chemoradiotherapy with weekly paclitaxel and cisplatin for five cycles along with radiotherapy delivered five days per week. The study dynamically monitors ctDNA levels at several points before treatment, before chemoradiotherapy, after 20 radiotherapy fractions, and every three months after treatment completion. During the study, participants undergo regular assessments including blood tests for ctDNA analysis and monitoring of tumor status. The main outcome measured is progression-free survival at one year. Safety and efficacy are tracked throughout the treatment and follow-up periods. The total participation duration and timing of assessments are carefully planned to evaluate the treatment strategy and its correlation with patient prognosis.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
2 locations
R

Actively Recruiting

Researchers are evaluating the use of robot-assisted stereotactic puncture surgery compared to conventional medical treatment for patients with brainstem hemorrhage. The study aims to create a multi-center clinical database, assess the effects of this minimally invasive surgery on survival and neurological outcomes, and improve the robotic surgical system with artificial intelligence for better planning and prediction. Participants are randomly assigned to either receive robot-assisted stereotactic minimally invasive surgery for brainstem hematoma puncture or conventional conservative medical management. The surgical procedure uses AI-based robotic navigation to plan and perform precise puncture and aspiration of the hematoma, with individualized surgical approaches based on imaging. The control group receives standard medical care that includes oxygen therapy, blood pressure control, sedation, and other supportive treatments. During the study, participants will be monitored for survival at 60 days, neurological function and recovery using various scales at 60 days and 6 months, quality of life, cognitive function, and hospital and ICU stay lengths. Imaging will assess hematoma clearance in the first week after surgery, and complications such as pneumonia or seizures will be tracked within 14 days. The study will last until June 2028, with ongoing evaluations to understand safety and efficacy of the robotic surgery approach.

Age: 18Years +All GendersPhase Not Applicable
15 locations
P

Actively Recruiting

Researchers are evaluating the anti-tumor effects of golidocitinib compared to investigators choice treatments in adults with relapsed or refractory peripheral T-cell lymphoma PTCL. This phase 3, open-label, randomized study includes patients who have confirmed PTCL and have not responded to or tolerated at least one prior systemic therapy. The study focuses on several PTCL subtypes and aims to improve treatment options for this condition. Participants will be randomly assigned to receive either golidocitinib orally once daily in repeated 21-day cycles or one of the investigators choice treatments, which may include chidamide taken orally twice a week or gemcitabine given intravenously on specific days within 28-day cycles. Treatments continue according to protocol with no masking or blinding involved. During the study, participants will be monitored for progression-free survival as the primary outcome, measured from the date of randomization until disease progression or death, over approximately four years. Secondary outcomes like overall survival will also be tracked. Eligibility assessments, compliance with contraceptive requirements, organ function tests, and ongoing safety monitoring will be part of the participant involvement throughout the study duration.

Age: 18Years +All GendersPhase 3
51 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the effects of royal jelly major proteins MRJPs delivered as rose tablet candies on ovarian function and endometrial receptivity in women aged 20 to 45 with normal menstrual cycles. The study will explore how MRJPs influence female reproductive health, focusing on their role in improving fertility factors such as hormone levels, ovarian reserve, and the uterine linings ability to support embryo implantation. It also seeks to determine the safety and potential clinical value of MRJPs for reproductive medicine. Participants will be randomly assigned to one of two groups one receiving oral MRJPs candy containing 70% MRJPs freeze-dried powder, and the other receiving a placebo candy mainly composed of whey protein powder. Both groups will take one tablet twice daily for one menstrual cycle. The MRJPs candy uses patented technologies to ensure quality and stability of the active ingredients. The placebo group allows comparison to evaluate the specific effects of MRJPs. Throughout the trial, researchers will monitor hormone levels, including anti-Mllerian hormone, and assess endometrial receptivity from enrollment through the one-month treatment period. Various tests and measurements will be conducted to track ovarian function and hormonal changes. The study is conducted with ethical oversight and scientific rigor to protect participants and ensure reliable results, with total participation lasting about one menstrual cycle plus screening and follow-up.

Age: 20Years - 45YearsFEMALEPhase Not Applicable
1 location

1-10 of 100

1